Clinical Trial Update: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for FasT CAR-T GC012F in high risk t_NDMM (transplant-eligible and non-durable multiple myeloma) patients across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• FasT CAR-T GC012F (GC012F)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN